CCIA
RVMD icon

Campbell & Co Investment Adviser’s Revolution Medicines RVMD Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,130
Closed -$2.83M – 1319
2026
Q1 		$2.83M Buy
+29,130
New +$2.94M 0.16% 183

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Campbell & Co Investment Adviser's RVMD Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 29,130 shares — an estimated $2.83M sold.

Campbell & Co Investment Adviser first reported a position in RVMD in Q1 2026 and held it in 1 quarter. The position peaked at $2.83M in Q1 2026. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 29,130 Revolution Medicines shares in Q2 2026, an estimated $2.83M.
  • Campbell & Co Investment Adviser first reported a position in Revolution Medicines in Q1 2026 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Revolution Medicines position peaked at $2.83M in Q1 2026.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.